AstraZeneca receives FDA approval for type 2 diabetes combination drug

AstraZeneca has announced that it has received approval from the US Food and Drug Administration (FDA) for Qtern, its type 2 diabetes combination therapy.

Qtern is designed to be taken orally once a day, with each tablet featuring ten milligrams of dapagliflozin and five milligrams of saxagliptin. The treatment is intended for patients with type 2 diabetes who have not been able to get their condition under control by taking each of these two drugs separately.

Initial trials involving the new combination therapy have shown its efficacy in improving glycaemic control in type 2 diabetic adults, when taken in conjunction with a healthier diet and increased exercise levels.

Elisabeth Bjork, vice-president and head of cardiovascular and metabolic diseases in the Global Medicines Development department at AstraZeneca, commented: "The approval of Qtern is good news for patients who may benefit from improved glycaemic control by adding a PP-4 inhibitor to a SGLT-2 inhibitor in a convenient once-daily tablet."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

Image: dolgachov via iStock